Edgewise Therapeutics Reports Third Quarter 2026 Financial Results
PR Newswire•04/11/2026•16:01 ET
0
Key Highlights
- ➤$1.396 billion upfront cash received from Servier for sevasemten and muscular dystrophy business
- ➤$1.348 billion gain on sevasemten sale lifted Q3 net income to $1,166.2 million
- ➤$1,743.9 million cash, equivalents and marketable securities held at September 30, 2026
- ➤EDG-7500 Phase 3 HCM trial expected to initiate by year-end 2026
- ➤First patient dosed in Phase 2 EQUINOX-HFpEF trial of EDG-15400
Expert Statements
Kevin Koch, President and Chief Executive Officer of Edgewise Therapeutics
“Our third quarter reflects continued execution across both cardiovascular programs”
Kevin Koch, President and Chief Executive Officer of Edgewise Therapeutics
“In HCM, positive CIRRUS-HCM Part D results and our JCI Insight publication reinforce the differentiated profile of EDG-7500, and we expect to initiate our Phase 3 trial by year-end 2026.”
Kevin Koch, President and Chief Executive Officer of Edgewise Therapeutics
“In parallel, we dosed our first patient in the Phase 2 EQUINOX-HFpEF trial of EDG-15400, our selective cardiac sarcomere modulator designed to address impaired cardiac relaxation in HFpEF.”
Edgewise Therapeutics Reports Third Quarter 2026 Financial Results PR Newswire
– Published the differentiated mechanism of action of EDG-7500 that targets the regulatory light chain –
Get started
Create a free account to read the full story.